SHORT-TERM OUTCOMES AFTER INTERIM TREATMENT WITH BROLUCIZUMAB
Sign Up to like & getrecommendations! Published in 2022 at "Retina"
DOI: 10.1097/iae.0000000000003418
Abstract: Short-term brolucizumab therapy may result in anatomical benefits that are maintained for at least 6 months after switching to an alternative anti–vascular endothelial growth factor treatment while minimizing the risk of brolucizumab-related intraocular inflammation. Purpose:… read more here.
Keywords: treatment brolucizumab; brolucizumab; eyes decreased; interim treatment ... See more keywords
Role of various semiquantitative parameters of 18F-FDG PET/CT studies for interim treatment response evaluation in non-small-cell lung cancer
Sign Up to like & getrecommendations! Published in 2017 at "Nuclear Medicine Communications"
DOI: 10.1097/mnm.0000000000000723
Abstract: Purpose The aim of this study was to prospectively evaluate the role of various semiquantitative parameters obtained from fluorine-18 fluorodeoxyglucose (18F-FDG) PET/CT in interim treatment response assessment in biopsy-proven non-small-cell lung cancer (NSCLC) and to… read more here.
Keywords: interim treatment; response; treatment response; fdg pet ... See more keywords
Predictive value of baseline 18F-FDG PET/CT and interim treatment response for the prognosis of patients with diffuse large B-cell lymphoma receiving R-CHOP chemotherapy
Sign Up to like & getrecommendations! Published in 2021 at "Oncology Letters"
DOI: 10.3892/ol.2020.12393
Abstract: The present study aimed to investigate the prognostic value of baseline 18F-FDG PET/CT quantitative parameters and interim treatment response, and to assess whether the combination of these could improve the predictive efficacy in patients with… read more here.
Keywords: pet; interim treatment; treatment response; response ... See more keywords